Transcription factor Zbtb1 interacts with bridging factor Lmo2 and maintains the T-lineage differentiation capacity of lymphoid progenitor cells

Received for publication, May 2, 2022, and in revised form, September 13, 2022 Published, Papers in Press, September 17, 2022
https://doi.org/10.1016/j.jbc.2022.102506

Maria Koizumi1,4, Yuichi Kama1,4, Ken-ichi Hirano4, Yusuke Endo4, Tomoaki Tanaka4, Ken-ichi Hirano4, Yusuke Endo4, Tomoaki Tanaka4, Katsuto Hozumi4, and Hiroyuki Hosokawa1*.

From the 1Department of Immunology, Tokai University School of Medicine, Isehara, Kanagawa, Japan; 2Laboratory of Medical Omics Research, Kazusa DNA Research Institute, Chiba, Japan; 3Department of Molecular Diagnosis, Graduate School of Medicine, Chiba University, Chiba, Japan; 4Institute of Medical Sciences, Tokai University, Isehara, Kanagawa, Japan

* For correspondence: Hiroyuki Hosokawa, hosokawa.hiroyuki.g@tokai.ac.jp.

Edited by Craig Cameron

Hematopoietic stem and progenitor cells can differentiate into all types of blood cells. Regulatory mechanisms underlying pluripotency in progenitors, such as the ability of lymphoid progenitor cells to differentiate into T-lineage, remain unclear. We have previously reported that LIM domain only 2 (Lmo2), a bridging factor in large transcriptional complexes, is essential to retain the ability of lymphoid progenitors to differentiate into T-lineage. However, biochemical characterization of Lmo2 protein complexes in physiological hematopoietic progenitors remains obscure. Here, we identified approximately 600 Lmo2-interacting molecules in a lymphoid progenitor cell line by two-step affinity purification with LC-MS/MS analysis. Zinc finger and BTB domain containing 1 (Zbtb1) and CBFA2/RUNX1 partner transcriptional corepressor 3 (Cbfα2t3) were found to be the functionally important binding partners of Lmo2. We determined CRISPR/Cas9-mediated acute disruption of Zbtb1 or Cbfα2t3 in the lymphoid progenitor or bone marrow–derived primary hematopoietic progenitor cells causes significant defects in the initiation of T-cell development when Notch signaling is activated. Our transcriptome analysis of Zbtb1- or Cbfα2t3-deficient lymphoid progenitors revealed that Tcf7 was a common target for both factors. Additionally, ChIP-seq analysis showed that Lmo2, Zbtb1, and Cbfα2t3 cobind to the Tcf7 upstream enhancer region, which is occupied by the Notch intracellular domain/RBPJ transcriptional complex after Notch stimulation, in lymphoid progenitors. Moreover, transcription with Tcf7 restored the defect in the T-lineage potential of Zbtb1-deficient lymphoid progenitors. Thus, in lymphoid progenitors, the Lmo2/Zbtb1/Cbfα2t3 complex directly binds to the Tcf7 locus and maintains responsiveness to the Notch-mediated inductive signaling to facilitate T-lineage differentiation.

T-cell development is initiated by Notch signaling when prethymic lymphoid progenitors (LPs) migrate into the thymus (1–3). LPs express Notch receptors, Notch1 and Notch2, on their surface, and the thymic epithelial cells provide a Notch-ligand, Delta-like 4 (DLL4), to trigger the T-lineage developmental program (4–8). The dominant roles of Notch signal in the initiation of T-lineage program have been well studied using in vitro T-cell culture systems with conditional or CRISPR/Cas9-mediated disruption of Notch receptors (4, 9, 10). The similarities in the gene expression profiles of in vitro generated T progenitors and their in vivo counterparts have been validated via transcriptomic analysis (11, 12). Notch-dependent progression of T progenitor stages is regulated by the timely activation and repression of transcription factors (10, 13, 14). Transcription factor 7 (Tcf7), encoding the TCF1 protein, and GATA-binding protein 3 (Gata3) are the earliest Notch target genes that act as crucial regulatory transcription factors for T-cell specification in the thymus (15–18).

Hematopoietic stem cells (HSCs) are maintained in the bone marrow (BM) and can differentiate into all types of blood cells. HSCs gradually differentiate into hematopoietic progenitor cells (HPCs) with a limited differentiation potential. LPs (or lymphoid-primed multipotent progenitors) retain the capacity to give rise to not only lymphoid lineage but also myeloid lineage cells (19). A small portion of LPs in the BM migrate into the thymus and become T cells. While the biochemical characteristics of transcription factors in differentiated hematopoietic cells have been extensively examined (20–25), those in physiological LPs, especially those responsible for maintaining the T-lineage potential, remain elusive. One of the greatest difficulties in handling LPs is their rarity in vivo. In addition, recent advances in single-cell multomics approaches combined with lineage tracing have clearly indicated that HPCs are highly heterogeneous (26, 27). To overcome these problems, LP cell lines derived from EBF transcription factor 1 (Ebf1)–deficient HSCs have been established by several different groups (28–31). Ebf1-deficient LP cells are not transformed cells and can be maintained under B-cell conditions with monolayers of stromal cells. They have homogeneous properties of LPs and their ability to

4 These authors contributed equally to this work.
* For correspondence: Hiroyuki Hosokawa, hosokawa.hiroyuki.g@tokai.ac.jp.

© 2022 THE AUTHORS. Published by Elsevier Inc on behalf of American Society for Biochemistry and Molecular Biology. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
differentiate into T-lineage via Notch stimulation in vivo and in vitro (30, 31).

LIM domain only 2 (Lmo2) organizes large transcriptional complexes with basic helix-loop-helix (bHLH) and GATA family members and others in hematological tumors (32, 33). Lmo2 is highly expressed in HSCs and HPCs, and is sharply downregulated in the early stages of T-cell development in the thymus (34). Dysregulation of Lmo2 expression induces T-cell acute lymphoblastic leukemia (35, 36). Reprogramming of hematopoietic stem and progenitor cells (HSPCs) from differentiated blood cells or fibroblasts is induced by the transient expression of combinations of several transcription factors, including Lmo2 (37, 38). These results suggest that Lmo2 is essential for the HSPC reprogramming and is involved in maintaining the pluripotency of HSPCs (39). However, the biochemical characteristics of Lmo2 in physiological HPCs remain unclear.

In our attempt to establish Ebfi-deficient LP cell lines, we unexpectedly established LP cell lines with or without T-lineage potential and found Lmo2 to be a transcription factor that is essential for maintaining the potential of LPs to differentiate into T-lineage (31). LP cell lines without T-lineage potential have significantly low Lmo2 expression, and the ability to differentiate into T cell is abrogated by the disruption of Lmo2 in LP cell lines with T-lineage potential. In LPs, Lmo2 directly binds to the Tcf7 locus, one of the earliest Notch target genes, and maintains a poised chromatin configuration for the appropriate activation of Tcf7, when Notch signaling is provided (31).

In this study, we performed the proteomics analysis of Lmo2 protein complexes in Ebfi-deficient LP cell lines. In addition to previously reported Lmo2-interacting molecules, such as Cbfa2t3, in blood tumors, Zbtb1 is a potential DNA-binding subunit of the Lmo2 complex in LPs. CRISPR/Cas9-mediated deletion of Zbtb1 or Cbfa2t3 in Ebfi-deficient LPs induced an acute loss of the ability to differentiate into T-lineage cells. Zbtb1 and Cbfa2t3 bound to the upstream region of the Tcf7 locus, which is co-occupied by Lmo2, and Zbtb1- or Cbfa2t3-deficient LPs showed decreased Tcf7 expression. Transduction of Tcf7 restored the T-lineage differentiation potential of Zbtb1-deficient LPs. Finally, we confirmed that the acute disruption of Zbtb1 or Cbfa2t3 in BM-derived primary HPCs resulted in a significantly decreased T-lineage potential. Taken together, we identified a novel Lmo2 binding partner, Zbtb1, and demonstrated functional importance of Zbtb1 and Cbfa2t3 in retaining the ability of LPs to differentiate into T-lineages.

**Results**

**Zbtb1 is a novel interacting molecule of Lmo2 in LPs**

Lmo2 acts as a bridging factor in large transcriptional complexes with transcription factors and chromatin remodeling-related factors (32, 33). To dissect the molecular mechanisms involved in the Lmo2-mediated maintenance of T-lineage potential in LPs, we performed proteomic analysis of Lmo2-interacting molecules. We took advantage of a highly tractable Ebfi-deficient LP cell line that retains its potential to differentiate into T-lineage by Notch stimulation in vivo and in vitro (31). Ebfi-deficient LPs were transduced with Myc- and Flag-tagged Lmo2 and subjected to two-step affinity purification followed by SDS-PAGE and silver staining (Fig. 1A). Analysis by LC-MS/MS identified more than 600 Lmo2-interacting molecules in physiological LPs, including the previously reported components of Lmo2 complexes in hematological cancer cell lines, Lyl1, Tal1, Ldb1, Tcf12, Tcf3, and Cbfa2t3 (also known as ETO2 or MTG16) (Fig. 1B and Table S1) (32, 33). Another member of the ETO family, Cbfa2t2 (MTGR1), was also identified with a relatively lower enrichment score (Fig. 1B and Table S1). Gene ontology analysis of Lmo2-interacting molecules showed that the proteins involved in the regulation of transcription and chromatin remodeling were highly enriched (Fig. 1C). In addition to the previously reported Lmo2-interacting transcriptional corepressor, Cbfa2t3 (40, 41), the novel Lmo2-associating transcription factor, Zbtb1, is known to play important roles in hematopoiesis and T-cell development (42–45). Their association with Lmo2 was repeatedly detected and had one of the highest signals in our mass spectrometry analyses (Fig. 1B and Table S1). The interactions between Lmo2 and Zbtb1 or Cbfa2t3 were validated via coimmunoprecipitation with immunoblotting in Ebfi-deficient LPs (Figs. 1D and S1A), and all three factors are coexpressed in primary common lymphoid progenitors (Fig. S1B) (34). Zbtb1 possesses the BTB domain and eight zinc finger domains. Among them, the six C-terminal zinc fingers of Zbtb1 could be involved in the interaction with Lmo2 (Fig. 1E). Thus, Zbtb1 and Cbfa2t3 may play important roles in Lmo2-mediated maintenance of T-lineage potential in LP cells.

**Zbtb1 is essential to retain the ability of LPs to differentiate into T-lineage**

To verify whether Zbtb1 and Cbfa2t3 are involved in the maintenance of the T-lineage potential, we performed CRISPR/Cas9-mediated acute disruption of Zbtb1 and Cbfa2t3 in Ebfi-deficient LPs (22, 31). Cas9-GFP-transduced Ebfi-deficient LPs were infected with bicistronic retroviral vectors carrying single-guide RNAs (sgRNAs) against luciferase (control), Lmo2, Zbtb1, Cbfa2t3, or Cbfa2t2 with human nerve growth factor receptor (hNGFR) marker. Specific losses of the targeted proteins were detected by immunoblotting in Cas9-expressing LPs, 4 days after sgRNA introduction (Fig. 2A). Five or ten days after sgRNA transduction, Cas9-GFP*sgRNA-hNGFR* Ebfi-deficient LPs were provided Notch stimulation via transferring onto a OP9-DLL4 monolayer to examine their capacity to differentiate into the T-lineage (Fig. 2B). Notably, deletion of Zbtb1 in Ebfi-deficient LPs slightly or significantly reduced cell recovery at 5 or 10 days post-sgRNA introduction (dpi), respectively, before Notch stimulation (Fig. S2, A and B). These results are agreed with previous reports showing the functional importance of Zbtb1 in preventing p53-mediated apoptosis in LPs (46, 47). Two days after DLL4-mediated Notch stimulation, the developmental status of sgRNA-transduced Ebfi-deficient
Figure 1. Identification of Lmo2-interacting molecules in LPs. A, Myc- and Flag-tagged Lmo2 was retrovirally transduced into Ebf1-deficient LPs. Total extracts from Myc-Flag-Lmo2-expressing LPs were subjected to two-step affinity purification followed by SDS-PAGE and silver staining. All of the visible bands were subjected to mass spectrometry analysis. B, representative Lmo2-binding molecules in LPs are shown with Mascot scores. The full list of the Lmo2-binding molecules is shown in Table S1. C, Gene Ontology (GO) annotation was performed using the DAVID analysis tool (http://david.ncifcrf.gov/). Top six GO terms for Lmo2-interacting molecules in Ebf1-deficient LPs are shown. D, total extracts from Mock or Myc-Flag-Lmo2 transduced LPs were subjected to immunoprecipitation (IP) with mouse control Ig or anti-Flag mAbs followed by immunoblotting with anti-Zbtb1, or anti-Cbfa2t3 Abs. Nuclear lysates (input) were also subjected to immunoblotting with anti-Zbtb1, anti-Cbfa2t3, anti-Myc (Lmo2), and anti-LaminB Abs. E, Lmo2 and Myc-Flag-tagged Zbtb1 mutants (WT, dBTB, or dZn) were transiently transduced into 293T cells. Total extracts from Lmo2 and Zbtb1 transduced 293T cells were subjected to immunoprecipitation with anti-Flag mAb followed by immunoblotting with anti-Lmo2 mAb. Nuclear lysates (input) were also subjected to immunoblotting with anti-Lmo2, anti-Myc (Zbtb1), and anti-LaminB Abs. Data are representative of two (D and E) or three (A) independent experiments. LP, lymphoid progenitor.
LPs was scored using the markers, CD44 and CD25, which distinguish CD4−CD8− (double-negative; DN) T progenitor stages (Fig. 2B, right) (2, 13). Deletion of Zbtb1 severely impaired the progression of LPs into DN2 (CD44+CD25+) stage at 5 and 10 days after sgZbtb1 transduction. These results suggest that LPs sharply lost the T-lineage potential in 5 days after acute disruption of Zbtb1, whereas, in agreement with a previous report (31), deletion of Lmo2 induced loss of ability to differentiate into T-lineage gradually, around 10 days (Figs. 2, C–F and S2, C and D). While Cbfa2t2 disruption did not have a
significant effect on the generation of CD25+ cells after Notch stimulation, Cbfa2t3-deficient LPs had modestly reduced DN2 cells at 5 dpi and were arrested at DN1 stage as well as Lmo2- or Zbtb1-deficient LPs at 10 dpi (Figs. 2, C–F and S2, C and D). Therefore, in addition to Lmo2, Zbtb1 and Cbfa2t3 would play a crucial role in the maintenance of T-lineage differentiation capacity triggered by Notch-signaling in LPs with minor effects on the cell recovery (Fig. S2A), while expression levels of Notch1 and Notch2 in Lmo2-, Zbtb1-, or Cbfa2t3-deficient LPs were comparable with those of sgControl-transduced cells (Fig. S2E).

**Zbtb1 regulates Tcf7 expression levels in LPs**

To explore Zbtb1 and Cbfa2t3 target genes, which are involved in the regulation of T-lineage potential, Cas9-GFP*sgRNA-hNGFR* LPs were sorted for transcriptome analysis (QuantSeq 3' mRNA sequencing) at 5 days post sgRNA transduction, where the Zbtb1 disruption had little impact on cell recovery (Fig. 3A). Differentially expressed genes (DEGs) affected by the disruption of Lmo2, Zbtb1, Cbfa2t2, and Cbfa2t3 were defined by p value <0.05, |Log2 fold change| >1 and average transcripts per kilobase million (TPM) >10 in the control or samples. The number of DEGs in Zbtb1 KO LPs, which had the most significant defect in T-lineage differentiation capacity among the samples, was 171, which was higher than that in Lmo2, Cbfa2t2, or Cbfa2t3 KO cells (~50 DEGs) (Table S2). Gene Ontology (GO) analysis showed that Zbtb1-regulated genes (171 DEGs in Zbtb1 KO LPs) were enriched for genes categorized to "stem cell differentiation" and "cell differentiation" (Fig. 3B). We previously showed that Tcf7 (encoding TCF1), the earliest Notch-activated gene, is a functionally important Lmo2 target in LPs (31). Among Notch-dependent T-lineage signature genes in the earliest T progenitors (DN1-DN2a stages) (10), the expression levels of Tcf7, Bcl11b, and Bcl11a were decreased in Zbtb1 or Cbfa2t3 disrupted LP cells (Fig. 3C), while some deviations among replicates were observed because of their low expression levels in LPs without Notch signaling (TPM values for Tcf7; sgCont 3.78 ± 2.03 versus sgZbtb1 0.49 ± 0.01). We confirmed these observations via reverse transcription-quantitative PCR analysis. Among two of the earliest Notch target genes, Tcf7 and Gata3 (Fig. S1B), the expression levels of Tcf7 were significantly decreased by the acute deletion of Zbtb1 or Cbfa2t3 but levels of Gata3 were not affected (Fig. 3D). Bcl11b, which is activated at the later time point
around the transition from DN2a to DN2b stages after Notch stimulation (Fig. S1B), was downregulated in not only Zbtb1- and Cbfa2t3-deficient but also Cbfa2t2-deficient LPs. The other Bcl11 family gene, Bcl11a, which is highly expressed in LPs (Fig. S1B) and has been reported to regulate the survival of LPs (48), had slightly lower mRNA and protein expression levels in the Zbtb1 KO LPs (Figs. 2A and 3D). These data, along with a previous report (31), demonstrate that Tcf7 appears to be a functionally important common target gene of Zbtb1, Cbfa2t3, and Lmo2 on the T-lineage differentiation capacity of LPs.

Zbtb1 binds to the upstream regions of the Tcf7 locus

The Zbtb1-sensitive genes are regulated both directly and indirectly. Thus, we performed chromatin immunoprecipitation followed by deep sequencing (ChIP-seq) for Zbtb1 and Cbfa2t3 in Ebf1-deficient LP cells and compared them with the Lmo2 occupancy genomic regions (31). Approximately 6000 of reproducible Zbtb1 and Cbfa2t3 binding peaks were detected across the genome, and the most enriched sequence was the Runx motif, which has been found around hematopoietic transcription factors, including Lmo2, E2A, PU.1, Bcl11b, or GATA3, occupancy sites (Fig. 4, A and B) (24, 31, 49, 50). The second enriched transcription factor–binding motifs were the Zbtb7c binding motif for Zbtb1 and the bHLH motif, which is also enriched around the Lmo2 binding regions (31), for Cbfa2t3 (Fig. 4, A and B). Indeed, more than 35% and 85% of the Lmo2 binding sites were co-occupied with Zbtb1 and Cbfa2t3, respectively, and 564 peaks were cobound by all three molecules (Fig. 4C). The expression levels of Bcl11a were moderately regulated by Lmo2 and Cbfa2t3 (Fig. 3D), and these two factors co-occupied the downstream regions of the Bcl11a locus without Zbtb1 binding (Fig. S3, rectangles). One of the representative sites cobound by Lmo2, Zbtb1, and Cbfa2t3 was the −35 kb upstream region of the Tcf7 locus, which overlapped with one of the RBPJ (also known as CSL), a DNA-binding subunit of the intracellular domain of Notch (Notch-IC) complex, binding sites after Notch stimulation (Fig. 4D, right rectangle) (10). We have previously reported

---

**Figure 4.** Lmo2/Cbfa2t3/Zbtb1 complex binds to the −35 kb region of the Tcf7 locus. A, chIP-seq analyses against Zbtb1 and Cbfa2t3 were performed using Ebf1-deficient LPs without Notch stimulation. The top three enriched sequence motifs among the 5898 reproducible Zbtb1 peaks are shown. B, top three enriched sequence of motifs among the 6077 reproducible Cbfa2t3 peaks are shown. C, Venn diagrams show the numbers of reproducible Zbtb1 and Cbfa2t3 ChIP peaks with the previously reported Lmo2 peaks (31) in Ebf1-deficient LPs. D, representative ChIP-seq tracks for Lmo2, Zbtb1, and Cbfa2t3 in Ebf1-deficient LPs without Notch stimulation, and RBPF in DN1 cells (10) around the Tcf7 locus are shown. The −31 and −35 kb RBPF-binding sites are labeled with rectangles. Data are based on ChIP-seq peaks scored as reproducible in two replicate samples (A–C), or representative of two independent experiments (D). ChIP-seq, chromatin immunoprecipitation followed by deep sequencing; DN, double-negative; LP, lymphoid progenitor.
that Lmo2 directly binds to the −35 kb upstream region of the Tcf7 locus and maintains DNA methylation status of the Tcf7 locus (31). Therefore, the Lmo2/Zbtb1/Cbfa2t3 complex appears to regulate the expression of Tcf7 via direct binding at the −35 kb region of the Tcf7 locus in LPs before the progenitor cells receive Notch signal. Importantly, a clear Zbtb1 peak and a modest Cbfa2t3 peak with almost no Lmo2 binding signal were detected at the other RBPJ-binding site in the −31 kb upstream region of the Tcf7 locus, which has been reported as a Notch-dependent enhancer region of Tcf7 (Fig. 4D, left rectangle) (15, 51). Thus, Zbtb1 may be involved in Notch-mediated activation of Tcf7 in Lmo2-dependent and Lmo2-independent mechanisms.

Defect in the T-lineage potential of Zbtb1-deficient LPs is recovered via Tcf7-transduction

Next, to test whether insufficient expression of Tcf7 led to the loss of T-lineage potential in Zbtb1-deficient LPs, we examined the effects of Tcf7 introduction in Zbtb1 KO LPs. Five days after the introduction of sgZbtb1, marked with a CFP reporter, LP cells were transduced with a second retrovirus encoding Tcf7-hNGFR and then cocultured with OP9-DLL4 to initiate T-lineage differentiation for 2 days (Fig. 5A). Transduction of Tcf7 dramatically restored the generation of CD44+CD25+ DN2 cells in Zbtb1-deficient LPs, while a partial rescue of cell recovery was observed after Tcf7 introduction (Figs. 5, B–D and S4A). Moreover, Tcf7-introduced Zbtb1-deficient LPs clearly expressed the intracellular TCRβ chain, 14 days after Notch stimulation (Fig. 5E). Consequently, these results suggest that Tcf7 is a major downstream target of Zbtb1 for the maintenance of the T-lineage capacity of LPs and that other mechanisms contribute to the regulation of Zbtb1-mediated proliferation and/or survival of LP cells.

Zbtb1 regulates the ability of primary BM progenitors to differentiate into T-lineage

Finally, we verified the effects of Zbtb1 disruption on the developmental potential of the T-lineage in primary cells. BM-derived hematopoietic progenitor cells from Rosa26-Cas9 knock-in mice with a Bcl2 transgene (Cas9;Bcl2 Tg), which enhances viable recovery of cells without altering T-cell development (52), were transduced with sgRNA against Zbtb1 or Cbfa2t3 and cultured without OP9 stromal cells for 2 days. The cells were then transferred onto an OP9-DLL1 monolayer to induce Notch signaling (Fig. 6A). Four days after Notch stimulation, the progression of early T-cell development was assessed using lineage markers (Lin), CD45, CD44, and CD25 expression. The percentages of Lin−CD45+CD44−CD25− cells (Fig. 6B, upper) and CD44+CD25+ cells (Fig. 6B, lower) were moderately reduced by disruption of Zbtb1 and Cbfa2t3, and the recovery of Lin−CD45+CD44+CD25+ DN2 cells in the cultures was significantly attenuated (Fig. 6, B and C). These results demonstrated that Zbtb1 and Cbfa2t3 regulate the capacity of primary hematopoietic progenitor cells to differentiate into T-lineage cells.

**Figure 5. Introduction of Tcf7 rescues the generation of CD25+ cells in Zbtb1-deficient LPs.** A, experimental scheme for the transduction of Tcf7 after the deletion of Zbtb1 in Ebf1-deficient LPs is shown. B, two days after Tcf7 (encoding TCF1 protein) transduction (A), GFP+CFP+hNGFR+ cells were gated and analyzed for intracellular TCF1 expression. Data are representative of two independent experiments. C, Cas9-GFP and sgRNA-CFP-transduced LPs were introduced with Tcf7-hNGFR, and transferred onto OP9-DLL4 stromal cells for 2 days. GFP+CFP+hNGFR+ cells were gated and analyzed for CD44 and CD25 expression. Data are representative of three independent experiments. D, the percentage of CD25+ cells among GFP+CFP+hNGFR+ cells (C) is shown with SD. The data represent the mean values of three independent biological replicates. **p < 0.01 by two-sided Student’s t test. E, fourteen days after Notch stimulation (A), GFP+CFP+hNGFR+ cells were gated and analyzed for intracellular TCRβ expression. Data are representative of two independent experiments. sgRNA, single-guide RNA.
Zbtb1 maintains T cell potential in lymphoid progenitors

A

Cas9;Bcl2 Tg BM progenitors sgRNA-hNGFR infection

2 days

OP9-DLL1 co-culture

4 days

FACS

B

sgControl

sgZbtb1

sgCbfa2t3

C

Figure 6. Zbtb1-deficient BM progenitors have attenuated ability to differentiate into T-lineage. A, experimental scheme for the deletion of Zbtb1 and Cbfa2t3 using the CRISPR/Cas9 system in BM progenitor cells is shown. BM progenitors obtained from Cas9;Bcl2 Tg mice were transduced with sgRNA against Zbtb1 and Cbfa2t3 and cultured without stroma cells for 2 days. Then, they were transferred onto OP9-DLL1 and cocultured for 4 days. HNGFR+ sgRNA-transduced cells were gated and analyzed for Lin markers, CD45, CD44, and CD25 expression. B, flow cytometric analysis of sgRNA-transduced BM progenitors cocultured with OP9-DLL1 for 4 days. Representative Lin/CD45 profiles in hNGFR+ sgRNA-introduced cells and CD44/CD25 profiles in hNGFR+Lin CD45high cells are shown. The results are representative of three independent experiments. C, the number of CD25+ cells among hNGFR+ sgRNA transduced cells (B) is shown with SD. The data represent the mean values of three independent biological replicates. **p < 0.01 by two-sided Student’s t test. BM, bone marrow; sgRNA, single-guide RNA.

Discussion

Biochemical analyses of Lmo2 protein complexes in blood tumor cells revealed that Lmo2 organizes large transcriptional complexes with bHLH and GATA family members. However, the subunits of Lmo2 complexes in physiological HPCs have remained obscure until now. We recently revealed that Lmo2 is required to maintain the ability of LPs to differentiate into T-lineage (31). Thus, in this study, we attempted to identify the functional binding partners of Lmo2, which are essential for the maintenance of T-lineage potential, in LPs using a biochemical approach. To purify the Lmo2 protein complexes, we employed an Ebf1-deficient LP cell line, which retained the ability to differentiate into T-lineage in a Notch signaling-dependent manner (31). In addition to the previously reported Lmo2-binding molecules in blood tumors, including Cbfa2t3, the transcription factor, Zbtb1, has been identified as a novel interacting partner of Lmo2 in LPs.

The functional importance of Zbtb1 in lymphopoiesis has been reported in two independent mouse models. The first model was established using a chemically induced mouse mutation system. A missense mutation of the conserved cysteine to arginine (C74R) in the BTB domain of Zbtb1 causes cell-intrinsic defects in lymphopoiesis, especially in the earliest stage of T-cell development; thus, this mouse model was named scanT (42). In another model, Zbtb1 was unexpectedly found as an insertion site of a transgene, which led to the T’ B’ NK’ severe combined immunodeficiency phenotype. A similar severe combined immunodeficiency phenotype has been observed in the germline disruption of Zbtb1 (43). Therefore, the loss of function of Zbtb1 clearly induces a disorder of lymphopoiesis, particularly in T-cell development (42, 43). However, the molecular mechanisms underlying how Zbtb1 controls the initiation of T-cell program have not been clarified. In this study, we showed that Zbtb1 directly binds to the Tcf7 locus, which is activated by the Notch-IC/RBPJ transcriptional complex to trigger T-cell development, as a component of the Lmo2 complex, and maintains the ability of LPs to differentiate into T-lineage. Zbtb1 deficiency had a much more striking effect than Cbfa2t3 or Lmo2 disruption in maintaining the T-lineage potential, especially 5 days after sgRNA transduction (Fig. 2). Lmo2 and Cbfa2t3 are non-DNA-binding components of the transcriptional complexes (32, 33, 45). In contrast, ZBTB family members are known to bind directly to specific DNA sequences via C-terminal zinc finger domains (53). The Zbtb1-binding sites detected by ChIP-seq analysis in LPs had a significantly enriched consensus motif for a ZBTB family member (Fig. 4A). Indeed, there is a 5’-TGGTGGT-3’ motif at the center of the ~35 kb upstream region of the Tcf7 transcriptional start site. Thus, Zbtb1 would act as a part of the DNA-binding subunits of the Lmo2 complex at the Tcf7 locus. This may be one of the reasons why Zbtb1 disruption quickly induced the loss of the ability to differentiate into T-lineage in LPs.

Zbtb1 disruption leads not only to defects in T-cell development but also to lower cell recovery (Fig. S2, A and B). Bcl11a has been reported as an essential transcription factor.
Zbtb1 maintains T cell potential in lymphoid progenitors

for the survival and proliferation of LPs via the activation of negative regulators of p53 activities, including Bcl2, Bcl-xl, and Mdm2 (48). In fact, expression levels of Bcl2 were modestly decreased in Zbtb1-deficient LPs (sgCont 678.5 TPM versus sgZbtb1 455.0 TPM, p < 0.01) (GSE199696). Therefore, the lower expression levels of Bcl11a in Zbtb1-deficient LPs (Figs. 2A and 3D) may contribute to this lower cell recovery. As there was no significant Zbtb1-binding signal around the Bcl11a locus (Fig. S3), Zbtb1 may regulate Bcl11a expression indirectly via the regulation of activators or repressors of Bcl11a or directly mediated by unknown distal cis-regulatory elements for Bcl11a. Zbtb1 has also been reported to be involved in maintaining genomic integrity. Zbtb1 regulates the recruitment of phosphorylated KAP-1 and RAD18 to DNA damage sites and subsequent DNA synthesis using error prone DNA polymerase to avoid cell death during DNA replication across damaged DNA (46). In addition, actively proliferating LPs from ScanT mice have a significantly higher frequency of p53-mediated apoptosis (47). Consequently, Zbtb1 may regulate the survival and proliferation of LPs via several distinct mechanisms.

In this study, we also examined the roles of the transcriptional corepressor Cbfa2t3, a previously reported Lmo2-interacting molecule in B-cell lymphoma and the erythrocytic lineage (40, 41). As shown here, approximately 85% of Lmo2 binding genomic regions were co-bound by Cbfa2t3 in LPs (Fig. 4C); thus, these factors closely cooperate to regulate gene expression across the genome. A significant defect in T-cell development has been observed in vivo and in vitro experimental systems using BM progenitors from Cbfa2t3-deficient mice (44, 45). Cbfa2t3 is not only involved in T lymphopoiesis but is also known to regulate the proper integration of Notch signals by interactions with Notch-IC and RBPJ. When Notch receptors interact with Notch ligands, Notch-IC is cleaved and translocated into the nucleus. Notch-IC organizes transcriptional complexes with RBPJ and activates its target genes (8). Cbfa2t3 interacts with RBPJ, prebinds to Notch target loci, and appears to regulate the repression and activation of Notch target genes, before and after Notch stimulation, respectively (44). This model fits to the role of the Lmo2/Cbfa2t3/Zbtb1 complex, which was found in this and previous reports, at the Tcf7 locus (31). Lmo2, Zbtb1, and Cbfa2t3 co-bound to the −31 kb region of the Tcf7 locus in LP cells before Notch stimulation and regulated Tcf7 expression activated by the Notch-IC/RBPJ complex when Notch stimulation was provided. Importantly, while re-expression of intact Cbfa2t3 into Cbfa2t3 disrupted hematopoietic progenitors restores the T-lineage potential, Cbfa2t3-deficient progenitors with the Cbfa2t3 mutant, which has a truncated Notch-IC binding domain, failed to differentiate into T-cells (44). Thus, prebinding of Lmo2 complexes, including Cbfa2t3, to Notch target loci in LPs would have a crucial role in the appropriate activation of Notch target genes, including Tcf7, and in triggering the T-cell differentiation program in the thymus.

TCF1, encoded by Tcf7, is an essential transcription factor in the earliest stages of T-cell development (54). Together with Runx transcription factors, Notch signaling is required to activate Tcf7 expression in T-cell progenitors (10, 12, 15, 22). There are two Notch-IC/RBPJ and Runx1 binding sites upstream of the Tcf7 locus at −31 kb and −35 kb regions (10, 12). Among these, the −31 kb region appears to be more important than the −35 kb region as a Notch-dependent enhancer of Tcf7 (15, 51). Although the physiological importance of the −35 kb region, a Lmo2/Cbfa2t3/Zbtb1 complex binding site, has not been clarified, our previous data suggest that Lmo2 maintains the transcriptionally poised chromatin state of the Tcf7 locus by direct binding to the −35 kb region in LPs (31, 51). Therefore, organization of the Lmo2/Cbfa2t3/Zbtb1 complex in the −35 kb region would play an important role in maintaining the accessible chromatin configuration of the Tcf7 locus and the ability to differentiate into T-lineage. In addition to the −35 kb region, Zbtb1 binds to the −31 kb region of the Tcf7 locus without cobinding of Lmo2 (Fig. 4D) (51). Thus, Zbtb1 would be involved in the regulation of Tcf7 expression in Lmo2-dependent and Lmo2-independent manners in the −35 kb and −31 kb regions, respectively. Only 10% of Zbtb1 binding genomic regions were co-occupied with Lmo2 (Fig. 4C). In addition, the expression of Zbtb1 is maintained at high levels not only during T-cell development in the thymus but also in mature T cells in the periphery, while Lmo2 and Cbfa2t3 expression are sharply downregulated after the earliest pro-T-cell stages in the thymus (Fig. S1B) (34). Therefore, the roles of Zbtb1 in T-cell development and function are thought to be beyond those of the Lmo2 complexes. Additionally, the importance of Zbtb1 in the generation of group 3 innate lymphoid cells (ILCs) has been reported (55). The lineage determination of ILCs from LPs is controlled by Tcf7 (56), and the initiation of Tcf7 expression is regulated by the −31 kb upstream regulatory element of the Tcf7 locus (51), where a strong Zbtb1-binding signal was observed in LPs (Fig. 4D). Thus, in addition to T-cell development, the Zbtb1-Tcf7 axis may contribute to the development of ILCs.

Here, we identified Zbtb1 as a novel functional subunit of the Lmo2 complex, using proteomic analysis and an acute deletion system in Ebf1-deficient LP cell lines. Moreover, the functional importance of Zbtb1 and Cbfa2t3 was confirmed in primary BM progenitors. Our results indicate that the T-lineage potential of LPs is actively maintained by the cooperative effects of various transcription factors, including Lmo2, Cbfa2t3, and Zbtb1 (Fig. S4B).

**Experimental procedures**

**Mice**

Ebf1-deficient mice were kindly provided by Dr Rudolf Grosschedl (Max Planck Institute of Immunobiology and Epigenetics) (57). B6.Cg-Tg(BCL2)25Wehi/J (Bcl2 Tg) (58) and B6.Gt(Rosa)26Sortm1.1(CAG-cas9*,-EGFP)Fehz/J (Rosa26-Cas9 knock-in) (59) mice were purchased from the Jackson Laboratory. All animals were bred and maintained in the animal facility of Tokai University School of Medicine, under specific pathogen-free conditions, and the protocol supporting animal
breeding for this work was reviewed and approved by the Animal Experimentation Committee of Tokai University.

**Cell culture of Ebfl-deficient lymphoid progenitor lines**

*Ebfl-*deficient lymphoid progenitor cell lines (31) were cultured in IMDM (Wako) with 10% fetal bovine serum (Sigma–Aldrich), penicillin–streptomycin–glutamine, 50 μM β-mercaptoethanol (Sigma–Aldrich), 10 ng/ml mouse SCF (PeproTech), 10 ng/ml human Flt3L (PeproTech), 10 ng/ml mouse IL-7 (PeproTech) with mitomycin C (Wako) treated OP9. For T-cell induction, lymphoid progenitors were cocultured on OP9-DLL4 for 2 days under the same conditions as the maintenance of the lymphoid progenitors.

**Flow cytometry**

For staining of sgRNA introduced LP cells, surface antibodies against Notch1 PE (BioLegend; 130607), Notch2 PE (BioLegend; 130707), CD44 PE(e780) (BioLegend; 103029), CD25 APC-e780 (BioLegend; 108704), CD19 (BioLegend; 115504), and CD3 [BioLegend; 108404], TER-119 [BioLegend; 116204], NK1.1 [BioLegend; 101204], CD11c [BioLegend; 117304], and CD11b [BioLegend; 117304], Gr-1 [BioLegend; 108404], TER-119 [BioLegend; 116204], NK1.1 [BioLegend; 108704], CD19 [BioLegend; 115504], and CD3ε [BioLegend; 100304], were incubated with magnet beads (Miltenyi Biotec), and passed through a magnetic column using AutoMACS with the ‘Deplete’ program (Miltenyi Biotec). The hematopoietic progenitors were infected with retroviral vectors encoding sgRNA and cultured using the OP9 medium (α-MEM (Sigma), 20% fetal bovine serum, 50 μM β-mercaptoethanol, Pen-Strep-Glutamine) supplemented with 10 ng/ml of human IL-7, 10 ng/ml of mouse SCF, and 10 ng/ml of human Flt3L for 2 days, then transferred onto OP9-DLL1 and cocultured for 4 days (60). The cultured cells were then disaggregated, filtered through a 40 μm nylon mesh, and subjected to flow cytometry analysis using surface antibodies against CD45 PE(e780) (BioLegend; 103113), CD44 FITC (BioLegend; 103005), CD25 APC-e780, human-NGFR PE, and a biotin-conjugated lineage cocktail (CD8α, BioLegend; 111034, CD11c, Gr-1, TER-119, NK1.1, CD19, TCRβ (BioLegend; 109204), and TCRγδ (BioLegend; 118103)) with streptavidin PerCP(e780) (BioLegend; 405214). Prior to cell surface staining, cells were treated with Fc blocker (Miltenyi).

**Cell culture of primary BM progenitors**

BM was removed from the femurs of 3- to 4-month-old Rosa26-Cas9 knock-in mice with a Bcl2 transgene (Cas9;Bcl2 Tg). Suspensions of BM cells were stained for lineage (Lin) markers using biotin-conjugated lineage antibodies (CD11b) (BioLegend; 101204), CD11c (BioLegend; 117304), Gr-1 (BioLegend; 108404), TER-119 (BioLegend; 116204), NK1.1 (BioLegend; 108704), CD19 (BioLegend; 115504), and CD3ε (BioLegend; 100304), then incubated with antibiotin magnetic beads (Miltenyi Biotec), and passed through a magnetic column using AutoMACS with the ‘Deplete’ program (Miltenyi Biotec). The hematopoietic progenitors were infected with retroviral vectors encoding sgRNA and cultured using the OP9 medium (α-MEM (Sigma), 20% fetal bovine serum, 50 μM β-mercaptoethanol, Pen-Strep-Glutamine) supplemented with 10 ng/ml of human IL-7, 10 ng/ml of mouse SCF, and 10 ng/ml of human Flt3L for 2 days, then transferred onto OP9-DLL1 and cocultured for 4 days (60). The cultured cells were then disaggregated, filtered through a 40 μm nylon mesh, and subjected to flow cytometry analysis using surface antibodies against CD45 PE(e780) (BioLegend; 103113), CD44 FITC (BioLegend; 103005), CD25 APC-e780, human-NGFR PE, and a biotin-conjugated lineage cocktail (CD8α, BioLegend; 111034, CD11c, Gr-1, TER-119, NK1.1, CD19, TCRβ (BioLegend; 109204), and TCRγδ (BioLegend; 118103)) with streptavidin PerCP(e780) (BioLegend; 405214). Prior to cell surface staining, cells were treated with Fc blocker (Miltenyi).

**Two-step affinity purification of Lmo2 complexes from lymphoid progenitors**

Lymphoid progenitor cells were infected with either mock control (pMxs-ires-hNGFR) or Myc-Flag-Lmo2-containing retrovirus. Three days after infection, Myc-Flag-tagged Lmo2-infected hNGFR⁺ cells were solubilized with the following protease inhibitor–containing immunoprecipitation buffer: 50 mM Tris–HCl (pH 7.5), 150 mM NaCl, 10% glycerol, 0.1% Tween, 1 mM EDTA, 10 mM NaF, 1 mM DTT, and a protease inhibitor cocktail (Roche Applied Science) and lysed on ice for 30 min with gentle shaking and sonicated on a VP-55 sonicator (TAITEC) for three cycles, amplitude 6 for 20 s, followed by 1 min rest. The insoluble materials were removed by centrifugation, and immunoprecipitation with mouse control Ig agarose (Sigma–Aldrich, A0919) or anti-Flag M2 agarose (Sigma–Aldrich, A2220) was performed overnight at 4 °C. Immune complexes were eluted from the agarose by 3×Flag peptide (Sigma–Aldrich), and the eluted Lmo2 complexes were subjected to a second immunoprecipitation with anti-Myc magnetic beads (MBL). Immune complexes were eluted from the magnetic beads with Myc peptide (MBL) and separated by SDS-PAGE. The bands were excised from the gel and subjected to a mass spectrometric analysis to identify corresponding proteins. The gel pieces were washed twice with 100 mM bicinecarbonate in acetonitrile, and the proteins were digested with trypsin. After adding 0.1% formic acid to the supernatant, the peptides were analyzed by LC-MS/MS with an Advance ultrahigh performance liquid chromatograph (Bruker) and an Orbitrap Velos Pro mass spectrometer (Thermo Fisher Scientific). The resulting tandem mass spectrometry dataset was analyzed using the Mascot software program (Matrix Science). Mascot score is the probability that the observed match is a random event (Mascot score > 100 means the absolute probability < 1e-10). GO analysis was performed using the DAVID analysis tool (https://david.ncifcrf.gov).

**Cloning**

Human *TCF7* complementary DNA was inserted into a multicloning site of the pMxs-ires-hNGFR vector. sgRNA expression vector (E42-dTet) and Cas9-GFP expression vector were described previously (22). 20-mer sgRNAs were designed using the Benchling web tool (https://www.benchling.com) and inserted into the empty sgRNA expression vector by PCR-based insertion. Two sgRNA expression vectors were generated for one gene, and pooled retroviral plasmids were used to make retroviral supernatant. Sequences of sgRNAs used in this study are listed below.

sgControl (Luciferase) #1; 5′-acccgccccctatgctcgccg-3′
sgControl (Luciferase) #2; 5′-ggcatgtcgagaactctcgc-3′
sgLmo2 #1; 5′-gcggagtctgctgtggcgcg-3′
sgLmo2 #2; 5′-cgcggcggccgctcgcggcggc-3′
sgZbtb1 #1; 5′-tgggaatggagaatggcag-3′
sgZbtb1 #2; 5′-tagtggagactgagatggac-3′
sgCbf2a2t2 #1; 5′-cagaatgcttgacgagcggc-3′
sgCbf2a2t2 #2; 5′-cgtactggcaggtg-3′

**Zbtb1 maintains T cell potential in lymphoid progenitors**

Ebf1 was reviewed and approved by the Animal Experimentation Committee of Tokai University.
reads with fastp. Trimmed reads of each sample were mapped to the reference mouse genome mm10 using STAR and normalized to one million reads in the original library. DEGs were defined with $p < 0.05$, $|\log2FC| > 1$, and TPM $> 10$ based on measurements from three biologically independent replicates for each sample type. GO analysis was performed using the DAVID analysis tool (https://david.ncifcrf.gov).

**ChIP-seq**

About $1 \times 10^7$ Ebf1-deficient LPs without Notch stimulation were transduced with $1$ mg/ml disuccinimidyl glutarate (Thermo Scientific) in PBS for $30$ min at room temperature followed by an additional $10$ min with addition of formaldehyde up to $1\%$. The reaction was quenched by addition of $1/10$ volume of $0.125$ M glycine and the cells were washed with Hanks’ balanced salt solution (Gibco). Pelleted nuclei were dissolved in lysis buffer (0.5% SDS, 10 mM EDTA, 0.5 mM EGTA, 50 mM Tris–HCl (pH 8) and PIC) and sonicated on a Bioruptor (Diagenode) for 18 cycles of 30 s sonication followed by 30 s rest, with high power. Five micrograms of anti-Zbtb1 Abs (a mixture of 2.5 μg of S303-242 (Bethyl) and 2.5 μg of ab79455 (Abcam)) or anti-Cbfa2t3 (a mixture of 2.5 μg of 17190-1-AP (Proteintech) and 2.5 μg of sc-373691 (Santa Cruz)) were prebound to Dynabeads anti-rabbit Ig or protein A/G (Invitrogen) and then added to the diluted chromatin complexes. The samples were incubated overnight at 4 °C, then washed and eluted for 6 h at 65 °C in ChIP elution buffer (20 mM Tris–HCl, pH 7.5, 5 mM EDTA, 50 mM NaCl, 1% SDS, and 50 μg/ml protease K). Eluted chromatin fragments were cleaned up using ChIP DNA Clean & Concentrator (Zymo). ChIP-seq libraries were constructed using NEBNext Ultra II DNA Library Prep with Sample Purification Beads (E7103S, NEB) and NEBNext Multiplex Oligos for Illumina (E7500S, NEB) and sequenced on Illumina NextSeq500 in single read mode with the read length of 75 nt. Base calls were performed with RTA 1.13.48.0 followed by conversion to FASTQ with bcl2fastq 1.8.4 and produced approximately 30 million reads per sample. ChIP-seq data were mapped to the mouse genome build NCBI37/mm10 using Bowtie (v1.1.1; http://bowtie.bio.sourceforge.net/index.shtml) with “-v 3 -k 11 -m 10 -t -best –strata” settings and HOMER tagdirectories were created with makeTagDirectory and visualized in the UCSC genome browser (http://genome.ucsc.edu). ChIP peaks were identified with findPeaks.pl against a matched control sample using the settings “-P .1 -L.P .1 -poisson .1 -style factor”. The identified peaks were annotated to genes with the annotatePeaks.pl command against the mm10 genomic build in the HOMER package. Peak reproducibility was determined by a HOMER adaptation of the IDR (Irreproducibility Discovery Rate) package according to ENCODE guidelines (https://sites.google.com/site/anshulkundaje/projects/idr). Only reproducible high quality peaks, with a normalized peak score ≥15, were considered for further analysis. Motif enrichment analysis was performed with the findMotifsGenome.pl command in the HOMER package using a 200 bp window.

**Statistical analysis**

The statistical significance of differences between datasets was determined using two-sided Student’s t test using Excel.
Zbtb1 maintains T cell potential in lymphoid progenitors

Statistical details of experiments can be found in the figure legends. In all figures, error bars indicate SD.

Data availability

The accession number for all the new deep-sequencing data reported in this paper is GEO: GSE199696.

Supporting information—This article contains supporting information.

Acknowledgments—We would like to thank Ellen V. Rothenberg and Maile Romero-Wolf for critical reading of the manuscript and helpful discussion. We thank members of the Support Center for Medical Research and Education at Tokai University for their technical help.

Author contributions—M. K. and H. H. conceptualization; M. K., Y. E., T. T., and H. H. formal analysis; M. K., Y. K., K.-I. H., Y. E., T. T., and H. H. data curation; M. K. and H. H. writing—original draft; Y. K., K.-I. H., Y. E., T. T., and K. H. writing—review and editing; M. K. and H. H. visualization; H. H. supervision; K. H. and H. H. project administration; M. K., K. H., and H. H. funding acquisition.

Funding and additional information—This work was supported by grants from the JSPS KAKENHI Grant Number JP19H03692, the Tokai University Tokuda Memorial Cancer/Genome Basic Research Grant for Young Investigators, the Tokyo Biochemical Research Foundation, The Uehara Memorial Foundation, The Naito Foundation, The Takeda Science Foundation, the Yasuda Medical Foundation, the Daiichi Sankyo Foundation of Life Science, the Research Grant of the Princess Takamatsu Cancer Research Fund, the Foundation for Promotion of Cancer Research, and The Mitsuishi Foundation (to H. H.), the 2021 Tokai University School of Medicine Research Aid (to M. K.), the JSPS KAKENHI Grant numbers 16K08848, 17H05802, and JP20K07330 (to K. H.), and the Cooperative Research Project Program of the Medical Institute of Bioregulation Kyushu University (to T. T.). This work was also partly supported by Research and Study Project of Tokai University General Research Organization to H. H.

Conflict of interest—The authors declare that they have no conflicts of interest with the contents of this article.

Abbreviations—The abbreviations used are: BM, bone marrow; ChIP-seq, chromatin immunoprecipitation followed by deep sequencing; DEG, differentially expressed gene; DN, double-negative; GO, Gene Ontology; HPC, hematopoietic progenitor cell; HSC, hematopoietic stem cell; HSPC, hematopoietic stem and progenitor cell; ILC, innate lymphoid cell; LP, lymphoid progenitor; sgRNA, single-guide RNA; TPM, transcripts per kilobase million.

References

specific cofactor recruitment and by repressing Id2 and Zbtb16. Nat. Immunol. 19, 1427–1440
31. Hirano, K. I., Hosokawa, H., Koizumi, M., Endo, Y., Yahata, T., Ando, K., et al. (2021) LMO2 is essential to maintain the ability of progenitors to differentiate into T-cell lineage in mice. Elife 10, e68227